@FiercePharma: IDEXX shares climb on record diagnostics placements and Q2 earnings gain. FierceAnimalHealth story | Follow @FiercePharma
@EricPFierce: ICYMI from FiercePharmaManufacturing: As Hospira expands recall of ketorolac to 37M vials you've got to wonder what Pfizer thinks. Story | Follow @EricPFierce
@CarlyHFierce: Celgene fights for sanction on patent challenger Bass. More | Follow @CarlyHFierce
> Roche's ($RHHBY) Perjeta has won a new indication in Europe for use with Herceptin before surgery in HER2-postive breast cancer patients. Story
> A new survey of general practitioners in three European countries found that they distrust mobile apps made by drugmakers. Report
> Australia's CSL says it has the approvals to complete its buyout of Novartis ($NVS) influenza vaccine business and is working with the Swiss drugmaker to complete the deal. Story
> The FDA is warning doctors and pharmacies to be careful not to confuse Brintellix, an antidepressant, with Brilinta, a blood-thinning medication. Report
Medical Device News
@FierceMedDev: FierceDiagnostics story: Foundation Medicine trips in Q2 with sluggish test reimbursement. More | Follow @FierceMedDev
@VarunSaxena2: ICYMI: NeuWave Medical gets FDA clearance for software upgrade to its ablation system. Report | Follow @VarunSaxena2
@EmilyWFierce: It's not a good week to be a drugmaker in Romania. More from FiercePharma | Follow @EmilyWFierce
> Upstart gets $6M to back the first FDA-cleared, OTC conception assistance device. Story
> Lombard Medical gains a second stent graft for aneurysm repair via $50M acquisition. Article
> CMS expands Medicare coverage of speech-generating devices. Report
Biotech News
@FierceBiotech: ICYMI yesterday: Failed Alzheimer's drug wins $117M in vTv's IPO. Article | Follow @FierceBiotech
@JohnCFierce: 125 ex-$GSK R&D staffers in RTP face the ax--again (Great industry. Where else can you get fired twice in 8 months?) News | Follow @JohnCFierce
> Amgen lops another 10% off its R&D budget amid wide cost cuts. Story
> Merck's Ebola vaccine is 100% successful in interim Phase III results. News
> AstraZeneca isn't giving up on brodalumab despite its links to suicide. Article